Bluebird plans to recycle revenues from its mining operations directly into bitcoin, aligning with what they describe as an innovative treasury approach. The company cited bitcoin’s fixed supply of 21 ...

PHOENIXVILLE — Bluebird Distilling, 100 Bridge St., has kicked off a renovation of the craft distillery, representing a full-scale transformation of the distillery and tasting room and the start ...

bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds manage ...

SOMERVILLE, Mass., June 02, 2025--bluebird bio (NASDAQ: BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by ...

Bluebird Distilling is undergoing a $2 million renovation to add a pizzeria and update its tasting room, coffee shop and bottle shop. The Phoenixville staple will remain open throughout ...

Bluebird is partnering with Teamwork Commerce to launch a next-generation RFID integration that transforms how retailers manage inventory. The integration pairs Bluebird’s high-performance RFR901 RFID ...

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital By Reuters May 14, 20257:11 AM PDTUpdated May 14, 2025 ...

Last week saw Lana Del Rey release “Henry, Come On,” the first taste of her new country era. Today (April 18), she’s back with more as she has shared another new single, the delicate ...

The bid comes after Bluebird had already agreed in February to be acquired and taken private by Carlyle and SK Capital Partners for $3 per share in cash, with the same $6.84 contingent value right.

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.